← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.

Tirzepatide

FDA approved · Rx

GIP / GLP-1 dual agonist

Also known as: Mounjaro, Zepbound

FDA approved and prescription only. Sold as Mounjaro (type 2 diabetes) and Zepbound (weight management).

Evidence score
90/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 305 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 1 cited source. Cited references provided

A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.

What's actually proven

Proven in large human trials: about 20% or more average weight loss at higher doses, and greater weight loss than semaglutide in head-to-head diabetes data. Strongly evidenced.

Half-life
About 5 days, which allows once-weekly dosing.
How it is used
Subcutaneous injection.

What it is

Activates two gut-hormone receptors (GIP and GLP-1) to improve insulin response, slow gastric emptying, and reduce appetite.

What the research says

Weight lossHuman trials

The SURMOUNT trials showed roughly 20% or more average body-weight reduction at higher doses.

Blood-sugar control in type 2 diabetesHuman trials

Approved on the SURPASS trial program; outperformed semaglutide in head-to-head diabetes data.

Registered human trials

Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Tirzepatide is the intervention being tested.

305registered studies
Phase 4most advanced phase
26+completed
33+recruiting now

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

Phase 3CompletedNCT03987919

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Phase 3CompletedNCT06588283

A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults

RecruitingNCT07364175

Anti-obesity Pharmacotherapy and Inflammation

Active Not RecruitingNCT05756764

Phase and status counts reflect the 100 most recent studies; the registered total above is exact.

FDA recalls & enforcement

No FDA recalls are on record for Tirzepatide.

Source: openFDA drug enforcement.

What people log it for

Descriptive, based on what users track. Not an endorsement or a suggested use.

Weight lossAppetite controlBlood sugar

Risks & unknowns

  • GI side effects similar to other GLP-1 drugs.
  • Muscle loss risk without protein and training.
  • Counterfeit and illegal research versions are common.
  • Prescription medicine: not for unsupervised use.

Doses reported in studies & protocols

Approved schedules escalate gradually under a prescriber. This is not a recommendation.

Purity reality

Like semaglutide, a heavy counterfeit target outside the pharmacy channel.

Verified lab data

None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.

How Verify will work →

Sources

We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.